Fundraising has long been a challenge for European biopharma companies, particularly those moving programs into the clinic, due to the limitations of European public markets. But change may be on the horizon.

With the rise of virtual fundraising, European innovators are finding new opportunities to access ex-EU public and private capital. But is this trend sustainable? Where does non-dilutive funding fit? Is a NASDAQ listing the right path? And what other tools should CEOs and their teams be considering as they advance their assets? In this episode, industry leaders unpack these critical questions and explore the evolving landscape of European biopharma fundraising.